Cancer cells are largely unable to change their metabolic programming as a result oftheir oncogenic alterations [87-91], which may underlie the sensitivity of HER2-overexpressing breast cancer cellsto growth factor receptor inhibitors, including trastuzumab and lapatinib. Here, ERBB2 is linked to breast cancer.